Ausgabe 2/2014
Inhalt (24 Artikel)
Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations
Marcello Maugeri-Saccà, Maddalena Barba, Patrizia Vici, Laura Pizzuti, Domenico Sergi, Ruggero De Maria, Luigi Di Lauro
Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
S. J. Ioannides, P. L. Barlow, J. M. Elwood, D. Porter
Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs
Amy Plotkin, Claude-Henry Volmar, Claes Wahlestedt, Nagi Ayad, Dorraya El-Ashry
High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF-β-dependent epithelial-mesenchymal transition in breast cancer
Cheng Zhang, Yong Han, Hao Huang, Like Qu, Chengchao Shou
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer
Julie M. Madden, Kelly L. Mueller, Aliccia Bollig-Fischer, Paul Stemmer, Raymond R. Mattingly, Julie L. Boerner
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer
Bharath Rudraraju, Marjolein Droog, Tarek M. A. Abdel-Fatah, Wilbert Zwart, Athina Giannoudis, Mohammed I. Malki, David Moore, Hetal Patel, Jacqui Shaw, Ian O. Ellis, Steve Chan, Greg N. Brooke, Ekaterina Nevedomskaya, Christiana Lo Nigro, Jason Carroll, R. Charles Coombes, Charlotte Bevan, Simak Ali, Carlo Palmieri
Outcomes of solid palpable masses assessed as BI-RADS 3 or 4A: a retrospective review
Stephanie K. Patterson, Colleen H. Neal, Deborah O. Jeffries, Annette Joe, Katherine Klein, Janet Bailey, Renee Pinsky, Chintana Paramagul, Kuanwong Watcharotone
Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy
Rei Mimoto, Tadashi Kobayashi, Yoshimi Imawari, Makiko Kamio, Kumiko Kato, Hiroko Nogi, Yasuo Toriumi, Shinichi Hirooka, Ken Uchida, Hiroshi Takeyama
Circulating tumor cells in non-metastatic triple-negative breast cancer
Mandar Karhade, Carolyn Hall, Priyankana Mishra, Amber Anderson, Henry Kuerer, Isabelle Bedrosian, Savitri Krishnamurthy, Anthony Lucci
Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate?
David K. Woolf, Anwar R. Padhani, N. Jane Taylor, Andrew Gogbashian, Sonia P. Li, Mark J. Beresford, Mei-Lin Ah-See, James Stirling, David J. Collins, Andreas Makris
Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer
Andreas D. Hartkopf, Diana Stefanescu, Markus Wallwiener, Markus Hahn, Sven Becker, Erich-Franz Solomayer, Tanja N. Fehm, Sara Y. Brucker, Florin-Andrei Taran
Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures
Chi-Cheng Huang, Shih-Hsin Tu, Heng-Hui Lien, Ching-Shui Huang, Chi-Jung Huang, Liang-Chuan Lai, Mon-Hsun Tsai, Eric Y. Chuang
Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients
Isabel T. Rubio, Martin Espinosa-Bravo, Maxi Rodrigo, Maria Amparo Viguri Diaz, David Hardisson, Amaia Sagasta, Basilio Dueñas, Vicente Peg
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival
Mala Pande, Melissa L. Bondy, Kim-Anh Do, Aysegul A. Sahin, Jun Ying, Gordon B. Mills, Patricia A. Thompson, Abenaa M. Brewster
Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program
Maegan V. Prummel, Susan J. Done, Derek Muradali, Vicky Majpruz, Patrick Brown, Hedy Jiang, Rene S. Shumak, Martin J. Yaffe, Claire M. B. Holloway, Anna M. Chiarelli
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
T. Byrski, T. Huzarski, R. Dent, E. Marczyk, M. Jasiowka, J. Gronwald, J. Jakubowicz, C. Cybulski, R. Wisniowski, D. Godlewski, J. Lubinski, S. A. Narod
Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer
Claudette Falato, Julie Lorent, Edneia Tani, Eva Karlsson, Paul K. Wright, Jonas Bergh, Theodoros Foukakis
Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study
E. H. Allott, C.-K. Tse, A. F. Olshan, L. A. Carey, P. G. Moorman, M. A. Troester
Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
Yifang Wei, Xiaofeng Lai, Shentong Yu, Suning Chen, Yongzheng Ma, Yuan Zhang, Huichen Li, Xingmei Zhu, Libo Yao, Jian Zhang
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
Vakaramoko Diaby, Georges Adunlin, Simon B. Zeichner, Kiran Avancha, Gilberto Lopes, Stefan Gluck, Alberto J. Montero
Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
Vakaramoko Diaby, Georges Adunlin, Simon B. Zeichner, Kiran Avancha, Gilberto Lopes, Stefan Gluck, Alberto J. Montero
Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation
Mary K. Askren, Misook Jung, Marc G. Berman, Min Zhang, Barbara Therrien, Scott Peltier, Lynn Ossher, Daniel F. Hayes, Patricia A. Reuter-Lorenz, Bernadine Cimprich
Unvalidated antibodies and misleading results
David Rimm, Kurt Schalper, Lajos Pusztai
Author’s response to “Letter to the editor: unvalidated antibodies and misleading results”
S. Muenst, A. Tzankov, W. E. Gillanders, S. D. Soysal